日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

克服紫杉烷耐药性:选择性糖皮质激素受体调节剂 Relacorilant 与白蛋白结合型紫杉醇在实体肿瘤中的临床前和 1 期研究

Pamela N Munster #, Andrew E Greenstein #, Gini F Fleming, Erkut Borazanci, Manish R Sharma, Joseph M Custodio, Iulia Cristina Tudor, Hristina I Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C Sachdev

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial

多斯塔利单抗(一种抗PD-1药物)在晚期实体瘤患者中的安全性、抗肿瘤活性和药代动力学:一项剂量递增的1期试验

Patnaik, Amita; Weiss, Glen J; Rasco, Drew W; Blaydorn, Lisa; Mirabella, Amy; Beeram, Murali; Guo, Wei; Lu, Sharon; Danaee, Hadi; McEachern, Kristen; Im, Ellie; Sachdev, Jasgit C

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

Capivasertib 对 AKT1 E17K 突变肿瘤患者的疗效:NCI-MATCH 子方案 EAY131-Y 非随机试验

Kalinsky, Kevin; Hong, Fangxin; McCourt, Carolyn K; Sachdev, Jasgit C; Mitchell, Edith P; Zwiebel, James A; Doyle, L Austin; McShane, Lisa M; Li, Shuli; Gray, Robert J; Rubinstein, Larry V; Patton, David; Williams, Paul M; Hamilton, Stanley R; Conley, Barbara A; O'Dwyer, Peter J; Harris, Lyndsay N; Arteaga, Carlos L; Chen, Alice P; Flaherty, Keith T

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

PF-06647020(Cofetuzumab Pelidotin)是一种靶向蛋白酪氨酸激酶7的抗体药物偶联物,在晚期实体瘤中的首次人体研究

Maitland, Michael L; Sachdev, Jasgit C; Sharma, Manish R; Moreno, Victor; Boni, Valentina; Kummar, Shivaani; Stringer-Reasor, Erica; Lakhani, Nehal; Moreau, Allison R; Xuan, Dawei; Li, Ray; Powell, Eric L; Jackson-Fisher, Amy; Bowers, Michelle; Alekar, Shilpa; Xin, Xiaohua; Tolcher, Anthony W; Calvo, Emiliano

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

脂质体伊立替康治疗转移性乳腺癌患者的 I 期研究:扩展阶段的研究结果

Sachdev, Jasgit C; Munster, Pamela; Northfelt, Donald W; Han, Hyo Sook; Ma, Cynthia; Maxwell, Fiona; Wang, Tiffany; Belanger, Bruce; Zhang, Bin; Moore, Yan; Thiagalingam, Arunthathi; Anders, Carey

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

imalumab (BAX69) 是一种全人源重组抗氧化巨噬细胞迁移抑制因子抗体,用于治疗晚期实体瘤的 I 期研究

Mahalingam, Devalingam; Patel, Manish R; Sachdev, Jasgit C; Hart, Lowell L; Halama, Niels; Ramanathan, Ramesh K; Sarantopoulos, John; Völkel, Dirk; Youssef, Ashraf; de Jong, Floris A; Tsimberidou, Apostolia Maria

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

尼拉帕尼联合帕博利珠单抗治疗复发性铂耐药卵巢癌患者的单臂1期和2期试验

Konstantinopoulos, Panagiotis A; Waggoner, Steven; Vidal, Gregory A; Mita, Monica; Moroney, John W; Holloway, Robert; Van Le, Linda; Sachdev, Jasgit C; Chapman-Davis, Eloise; Colon-Otero, Gerardo; Penson, Richard T; Matulonis, Ursula A; Kim, Young Bae; Moore, Kathleen N; Swisher, Elizabeth M; Färkkilä, Anniina; D'Andrea, Alan; Stringer-Reasor, Erica; Wang, Jing; Buerstatte, Nathan; Arora, Sujata; Graham, Julie R; Bobilev, Dmitri; Dezube, Bruce J; Munster, Pamela